













# AGENDA

- Pharmaceutical R&D Pathologies
- **De-risking through Open Science**
- Open Public-Private Consortia: SGC
- Open Business Models: M4K Pharma
- Other Economic Benefits
- Policy Recommendations





























































## Future M4X Opportunities

- Disease represents a significant unmet therapeutic need
- Strong therapeutic hypothesis for a novel target but the disease does not fit historical pharma business models
- Initial technology is derived from the expertise of one of our existing, or future, collaboration partners

# AGENDA

- Pharmaceutical R&D Pathologies
- De-risking through Open Science
- Open Public–Private Consortia: SGC
- Open Business Models: M4K Pharma
- **Other Economic Benefits**
- Policy Recommendations



# AGENDA

- Pharmaceutical R&D Pathologies
- De-risking through Open Science
- Open Public-Private Consortia: SGC
- Open Business Models: M4K Pharma
- Other Economic Benefits
- **Policy Recommendations**



